vindesine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vinca alkaloids	2826	53643-48-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: eldisine desacetylvinblastine amide vindesine sulfate vindesine compound 112531	Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). Molecular weight: 753.94 Formula: C43H55N5O7 CLOGP: 3.42 LIPINSKI: 2 HAC: 12 HDO: 5 TPSA: 164.82 ALOGS: -4.03 ROTB: 7

Molecule

Description

Molfile Inchi Smiles

Synonyms:

eldisine
desacetylvinblastine amide
vindesine sulfate
vindesine
compound 112531

Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).

Molecular weight: 753.94
Formula: C43H55N5O7
CLOGP: 3.42
LIPINSKI: 2
HAC: 12
HDO: 5
TPSA: 164.82
ALOGS: -4.03
ROTB: 7

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
Vd (Volume of distribution)	5 L/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	35 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.14 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1979	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	484.06	60.35	106	1037	23597	63464282
Bone marrow failure	170.06	60.35	48	1095	29242	63458637
Leukopenia	83.04	60.35	36	1107	77254	63410625

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	469.02	37.15	128	2146	19137	34935520
Bone marrow failure	276.39	37.15	94	2180	29159	34925498
Stomatitis	86.50	37.15	46	2228	42468	34912189
Leukopenia	64.98	37.15	44	2230	62812	34891845
Febrile neutropenia	62.04	37.15	59	2215	136790	34817867
Agranulocytosis	57.67	37.15	29	2245	23792	34930865
Large intestine infection	45.73	37.15	12	2262	1506	34953151
Pyrexia	43	37.15	77	2197	332936	34621721

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	891.46	39.94	229	3310	40067	79700782
Bone marrow failure	450.50	39.94	142	3397	50965	79689884
Leukopenia	142.34	39.94	79	3460	116434	79624415
Agranulocytosis	97.41	39.94	45	3494	44985	79695864
Febrile neutropenia	87.12	39.94	76	3463	230923	79509926
White blood cell count decreased	79.23	39.94	66	3473	188222	79552627
Pyrexia	74.36	39.94	118	3421	678591	79062258
Stomatitis	64.93	39.94	53	3486	146704	79594145
Granulocytopenia	50.39	39.94	19	3520	11412	79729437
Neutrophil count decreased	43.77	39.94	35	3504	93924	79646925

Showing 1 to 10 of 12 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01CA03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues
CHEBI has role	CHEBI:35610	antineoplastic agents
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000972	Antineoplastic Agents, Phytogenic
MeSH PA	D050257	Tubulin Modulators

Showing 1 to 6 of 6 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Acute lymphoid leukemia	indication	91857003	DOID:9952
Chronic myeloid leukemia	indication	92818009	DOID:8552
Malignant tumor of lung	indication	363358000
Malignant melanoma	indication	372244006

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.64	acidic
pKa2	13.81	acidic
pKa3	7.86	Basic
pKa4	6.98	Basic
pKa5	6.15	Basic

Showing 1 to 5 of 5 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Km	4.61		WOMBAT-PK

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
003505	NDDF
003506	NDDF
11204	RXNORM
349851002	SNOMEDCT_US
3927	INN_ID
395921004	SNOMEDCT_US
4025282	VUID
4025282	VANDF
4025283	VANDF
40839	PUBCHEM_CID

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

None